French National Registry of Adults With Growth Hormone Deficiency Treated With Somatropin
Information source: Novo Nordisk A/S
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Growth Hormone Disorder; Adult Growth Hormone Deficiency
Intervention: somatropin (Drug)
Phase: N/A
Status: Completed
Sponsored by: Novo Nordisk A/S Official(s) and/or principal investigator(s):
Global Clinical Registry (GCR, 1452), Study Director, Affiliation: Novo Nordisk A/S
Summary
This study is conducted in Europe. The aim of this study is to extract data from the French
National Registry holding information about patients having initiated growth hormone therapy
with the objective to describe patients receiving growth hormone therapy, assess efficacy
and safety of somatropin (Norditropin® SimpleXx®) and evaluate treatment compliance.
Clinical Details
Official title: Prospective, Longitudinal and National Follow-up Program of Adult Patients With Somatotropic Hormone Deficiency for Whom Substituting Treatment by Norditropin SimpleXx Was Started
Study design: Observational Model: Cohort, Time Perspective: Prospective
Primary outcome: WeightBody composition Waist:Hip Ratio Body mass index (BMI)
Secondary outcome: IGF-1 (Insulin-like growth factor 1) concentrationLipids: Total cholesterol, high-density lipoprotein (HDL), low-density lipoprotein (LDL) and triglycerides Dose prescribed
Eligibility
Minimum age: N/A.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Adult with growth hormone deficiency
- Treated with Norditropin® SimpleXx (somatropin)
Locations and Contacts
Lyon 69394, France
Additional Information
Clinical Trials at Novo Nordisk
Starting date: July 2003
Last updated: April 29, 2014
|
